Novo Nordisk, the Danish drugmaker that overtook LVMH to become Europe’s most valuable company in 2023 thanks to its Ozempic and Wegovy weight-loss drugs, is facing a difficult period. Its U.S. rival Eli Lilly has eaten into its market share, with its share price nearly doubling since 2024 while Novo Nordisk’s has fallen 70%. The company announced 9,000 job cuts in September 2025 to reduce costs by $1.2 billion, and a failed phase three trial for its cardiovascular drug ziltivekimab sent its share price down 10%. Despite these setbacks, Novo Nordisk will soon launch its Wegovy pill in Germany and is betting on 80% annual volume growth in the global weight-loss drug market.
Source: Read the original article
